In cancer, Type I IFNs promote multiple steps of the cancer-immunity cycle, including the maturation of dendritic cells (DC), the cross-priming of tumor-associated antigens (TAAs) between DCs and CD8+ T-cells, and the recruitment of cytotoxic T lymphocytes (CTLs) to the site of the tumor13–15. The gene discussed is CD8A; the disease is cancer.